Based on the literature done by others and our group, this roteinases, which, when activated, digest connective tissue article reviews the influence of ERT or HRT on such elements within the vessel wall and thin the fibrous cap aspects of endothelial function as vasomotor function and overlying vulnerable plaques, with the potential for plaque inflammation as plausible mechanisms in the prevention of rupture and exposure of the thrombogenic contents of the atherosclerosis and coronary heart disease in postplaque to blood [23] . menopausal women. We recently reviewed the effects of Endothelial dysfunction and reduced NO could also HRT on hemostasis and thus will not discuss this topic in stimulate the synthesis and release of endothelin, resulting this review [16] .
in enhanced vasoconstrictor tone; promote the release and activity of growth factors, resulting in smooth muscle hyperplasia and migration into the intima; and enhance the 2 . Inflammation and atherosclerosis synthesis and release of proinflammatory cytokines. Additionally, reduced NO could promote platelet attachment Growing evidence over the past decade implicates and release of growth factors in the vessel wall. All of chronic inflammation in the pathogenesis of atherosclerosis these consequences of endothelial dysfunction and reduced ( Fig. 1) [3] . Human coronary, carotid, and aortic speci-NO bioactivity may be important in the initiation, promens at necropsy have shown infiltration of the intima and gression, and clinical expression of atherosclerosis. In this media by granulocytes, lymphocytes, monocytes, and regard, the transition from stable to unstable angina macrophages [17] [18] [19] . The initiation of inflammation is appears to be associated with a systemic inflammatory probably multifactorial; more recently described risk facresponse [24] , and markers of acute inflammation (includtors include infectious pathogens [20] , homocysteine [21] , ing cytokines, C-reactive protein and white cell count) are and lipoprotein(a) [Lp(a)] [22] .
all related to increased cardiovascular risk [24, 25] . Once activated by injury, endothelial and smooth muscle cells of large arteries become transcriptionally active and synthesize proinflammatory proteins, including: (1) 3 . Mechanisms of estrogen's effects on the vascular chemokines and cell adhesion molecules (CAMs), which wall attract circulating inflammatory cells to the arterial surface and facilitate their attachment and incorporation into the Both endothelial cells and vascular smooth muscle cells vessel wall; (2) cytokines that activate inflammatory cells possess estrogen receptors and are thus physiological and transform monocytes into macrophages; (3) growth targets for estrogen action [26, 27] . Estrogen receptor a factors that stimulate smooth muscle cell proliferation; (4) (ERa) and b have been identified and both of these angiogenic peptides that increase the vascularity within the receptors are expressed and functional in cardiovascular arterial wall; and (5) prothrombogenic substances such as tissues, supporting a direct role for estrogen in cartissue factor and thromboxane. Cytokine-activated macrodiovascular physiology. Cellular responses elicited by phages and smooth muscle cells secrete matrix metallopestrogen may be achieved via both genomic and nongenomic mechanisms. Estrogen regulates the transcripdirectly stimulate the release of NO as shown in endothelition of numerous genes, and its cellular actions are al cells in culture [34] [35] [36] . The rapid effects of estrogen on mediated through the translation of specific mRNA transtimulation of NOS activity could be mediated by a known scripts and synthesis of proteins. Nongenomic responses to estrogen receptor, perhaps located in the plasma membrane estrogen occur more rapidly and do not rely on the [37] and able to activate NOS rapidly in a nongenomic activation of specific gene products [28] .
manner. ERa can directly activate endothelial NOS An important transcriptional target of estrogen is the (eNOS), perhaps through a tyrosine kinase pathway or the nitric oxide synthase (NOS) gene. Estrogen stimulates the mitogen-activated protein kinase signaling pathway [38] . constitutive synthesis of NO in numerous tissues, including
In this regard, one recent paper provided evidence that blood vessels, heart, uterus, and skeletal muscle. Both activation of eNOS in endothelial cells by ERa involves pregnancy and estrogen therapy enhance neuronal (NOS-I) the phosphatidylinositol 3 (PI3)-kinase-Akt pathway [39] .
2
and endothelial (NOS-III) NOS expression, whereas the They demonstrated inhibition of estrogen-induced NO 2 inducible NOS isoform (NOS-II) is unaffected [29] . Furrelease by a pharmacological inhibitor of PI3-kinase and thermore, the 59-flanking region of the gene for NOS-III showed that 17b-estradiol (E ) and E -BSA increased the 2 2 contains transcription factor-binding sites for estrogen phosphorylation of both Akt and eNOS. Another study [30] . Thus, estrogen regulates the activity of the NOS-III demonstrated Akt in the activation of eNOS by estrogen isoform by genomic mechanisms.
and provided substantial additional insight into the signal Reduction in vessel wall concentration of oxidized LDL transduction pathway involved in ERa-eNOS activation may improve NO synthesis, release, and biological activi- [40] . They observed a direct interaction of ERa with the ty. Reduction in levels of Lp(a) could also enhance NO p85 regulatory subunit of PI3-kinase. Of interest, a recent bioavailability if concentrations of oxidized Lp(a), which study presented localizing the functional ERa-eNOS can also inhibit NO bioactivity [31] , were reduced in the signaling complex to endothelial cell caveolae, the memvessel wall. HDL has been shown to protect LDL from brane microdomains well-known to be enriched in many oxidation [32] , and, if in proximity to LDL within the signaling molecules [41] . These investigators provided vessel wall, could indirectly augment NO bioactivity via immunological evidence that ERawas expressed in its antioxidant effect on LDL. In addition to reducing caveolae using both amino-and carboxy-terminal domain. circulating LDL levels, estrogen protects LDL from oxidaTaken together, these three recent studies allow construction [33] , which could indirectly enhance NO bioactivity tion of a model of this interesting new signal transduction by reducing the vessel wall concentration of oxidized pathway that now can be tested and further refined [42] LDL.
( Fig. 2) . These rapid effects do not require changes in gene Meanwhile, estrogen may also augment the bioactivity expression but may involve proteins that interact with the of NO independent of lipoprotein effects. Estrogen may ER, such as heat-shock protein 90, which also binds to and Fig. 2 . Composite model of nongenomic, ER-mediated activation of eNOS, based on published data [39] [40] [41] . These recent studies show immunological localization of ERa to caveolae, direct interaction of ERa with the p85 subunit of PI3-kinase, and activation of the PI3-kinase-Akt-eNOS pathway. However, many issues remain unresolved, in particular, including whether the ERa hormone-binding domain is actually inside or outside the membrane, how this ERa is tethered to the caveolae, and the precise primary sequence of this membrane-associated ER. For details, see text. Used with permission from Dr Mendelsohn [42] .
activates eNOS [43] . Estrogen rapidly causes coronary mg / day MPA. Lp(a) was also significantly reduced from vasodilatation ex vivo [27, 44] and in vivo in cholesterolbaseline. fed ovariectomized primates [45] and other animals [46] . The short-term coronary vasodilatory effects of estrogen in 4 .2. Effects of estrogen on LDL oxidation humans are largely mediated by the increased production of NO [47] .
Experimental evidence strongly indicates that LDL, Augmented bioactivity of NO by estrogen either inespecially following oxidative modification within the directly by its effect on lipoprotein levels and protection of vessel wall by free radical molecules [59] , may signifi-LDL from oxidation, or directly by effects on NO syncantly affect endothelial NO production and bioactivity thesis and release, might account not only for enhancement [60] . Therapeutic reduction in circulating LDL levels of endothelium-dependent vasodilation following estrogen presumably reduces the vascular wall transit and extraceladministration to postmenopausal women [48] [49] [50] but also lular matrix entrapment of these particles, which might for much of the anti-atherogenic effects of estrogen by reduce tissue concentrations of oxidized LDL. inhibition of platelet aggregation, platelet and inflamma-E has antioxidant effects in vitro [61] . However, it 2 tory cell attachment to the endothelial surface of the vessel remains unclear whether in vitro antioxidant effects of wall, and release of factors that stimulate growth and estradiol are physiologically important, since in most migration of smooth muscle cells within the vessel wall studies very high concentrations of estrogen were used. [51] .
Although Sack et al.
[33] demonstrated that both long-and short-term administration of physiologic concentrations of E decreased the oxidation of LDL cholesterol, in our 2 recent study examining the effects of CEE, we did not find 4 . Biological effects of estrogen any protection of LDL from oxidation following 1 month of administration to 30 women [52] . A larger study in 56 4 .
Effects of estrogen on lipoproteins
women also found no change in LDL oxidation using CEE, among other forms of ERT and HRT [62] . In Orally administered estrogens lower serum levels of contrast, Wilcox et al. [63] found significant inhibition in low-density lipoprotein (LDL) cholesterol and raise levels vivo of LDL oxidation by estrone sulfate, equilin sulfate, of high-density lipoprotein (HDL) cholesterol each by and 17a-dihydroequilin sulfate in postmenopausal women. approximately 15% and raise levels of triglyceride by
In vitro, CEE was effective in inhibiting both fatty acid approximately 20-25% in postmenopausal women [13] .
and LDL oxidation [61] . The route of administration of estrogen influences its CEE may conceivably lack an antioxidant effect because effects on serum lipids. Transdermally administered esit is comprised primarily of equine estrogens: the one trogens have less of an effect on serum lipid concentrations human-like estrogen contained in this preparation (estrone) than do orally administered estrogens. Coadministration of is a weaker antioxidant than E [61] . Although some 2 a progestin can blunt the changes in serum lipids due to estrone is converted to E , the serum levels of this 2 estrogen [13, 52] . Human and animal studies show that a antioxidant form of estrogen are approximately one-third decrease in the total LDL to HDL cholesterol ratio the levels achievable by direct administration of E . 2 enhances the clearance and metabolism of cholesterol Of related interest, ERT had no effect on LDL oxesters. Indeed, autopsy examination of the hearts of 113 idizability in postmenopausal women with type II diabetes men with coronary disease who had died suddenly remellitus [64] ; however, plasma levels of HDL cholesterol, vealed that an elevated total LDL / HDL cholesterol ratio apolipoprotein (apo) A-I, LDL cholesterol, apoB, and was associated with rupture of vulnerable plaques [53] . glycated hemoglobin were improved, indicative of a better We demonstrated that 0.625 mg of conjugated equine metabolic control. Since 19% of participants in the Heart estrogens (CEE) significantly reduced total LDL / HDL and Estrogen / progestin Replacement Study (HERS) were cholesterol ratio compared with pretreatment levels in diabetic, the lack of an inhibition of LDL oxidation may be postmenopausal women [54, 55] . ERT has also been shown one reason why HRT users did not benefit in the first year to reduce serum levels of Lp(a) [54] [55] [56] , a lipoprotein that of treatment [11] . Indeed, we observed that the effects of has structural features of LDL and plasminogen believed to ERT on endothelial function-vascular dilator and other be proatherogenic and anti-thrombolytic, and that increases homeostatic functions were less apparent in type II diabetic in serum concentration following menopause [57] . These postmenopausal women, despite beneficial effects of esfavorable changes were also seen in a recent randomized, trogen on lipoprotein levels [65] . double-blind, placebo-controlled trial [58] using lower doses of HRT than commonly prescribed. For example, the 4 .3. Effects of estrogen on vasomotion increase in HDL in women treated with 0.45 mg / day CEE plus 1.5 mg / day medroxyprogesterone acetate (MPA) after Endothelium-dependent vasodilation has been studied in 1 year was similar to that seen with 0.625 mg / day plus 2.5 both the coronary and peripheral circulation. Williams and colleagues [66] have demonstrated that when oophorecobserved that CEE 0.625 mg combined with MP or MPA tomized monkeys are fed a high-lipid diet, acetylcholine improved flow-mediated brachial artery dilator response to causes coronary vasoconstriction when infused into the hyperemia in 20 healthy postmenopausal women [72] . Of coronary vessels, suggesting loss of endothelial cell funcinterest, Vehkavaara et al. [73] reported that oral E -2 tion. When these monkeys received ERT, however, the induced increase in endothelium-dependent vasodilation infusion of acetylcholine caused vasodilation, as it does in could be explained not by acute estradiol effects but by normal animals. Indeed, E infused into the left coronary several antiatherogenic changes in lipoproteins in contrast 2 arteries of 20 postmenopausal women enhanced acetylto transdermal estradiol showing no effects on both choline-stimulated increases in coronary flow [48] . This endothelium-dependent vasodilation and lipoproteins. effect of estrogen on improvement of vasomotion may be In summary, although few studies observed no effect of due to potentiation of the activity of NO [47] and estrogen on endothelium-dependent vasodilation, most prostacyclin synthase [28] and decrease in potent vasoconstudies reported that oral estrogen increased endotheliumstrictor endothelin-1 levels [46, 67, 68] . Finally, E infused dependent vasodilation, which contributes to the preven-2 into the brachial arteries of postmenopausal women ention of CVD in postmenopausal women. hanced acetylcholine-stimulated forearm blood flow [49] .
We found that CEE 0.625 mg administered to 28 4 .4. Effects of estrogen on inflammation hypercholesterolemic postmenopausal women improved flow-mediated dilation comparable to the effect of simvas-
The gene transcription of many adhesion molecules, tatin 10 mg daily, despite greater reduction in LDL including vascular CAM-1 (VCAM-1) and intercellular cholesterol levels with simvastatin [54] . Lieberman et al.
CAM-1 (ICAM-1), is regulated by a nuclear transcription [50] reported that oral E resulted in significant improvefactor, NF-kB, normally maintained in an inactive state 2 ment in flow-mediated brachial artery dilation compared [74] . In addition to VCAM-1, ICAM-1, and E-selectin, with placebo. Hashimoto et al. [69] observed that flow-NF-kB also activates transcription of genes encoding mediated brachial artery diameter was greater during the chemoattractant factors, such as monocyte chemotactic follicular or luteal phase (when serum E level was high) peptide and macrophage stimulatory factor, that attract 2 than during the menstrual phase (when serum E level was monocytes into the vessel wall (Fig. 3) . NF-kB additional-2 low) in 17 premenopausal women. Gerhard et al. [70] ly increases the synthesis and release of cytokines such as observed that intravaginal MP added to E did not interleukin (IL)-1, IL-2, and IL-6, which activate inflam-2 significantly attenuate the improvement in flow-mediated matory cells, enhancing their attachment to the vessel wall dilation that was observed with E alone. In contrast, [75] . Harnish et al. found that E bound to the ERa 2 2 Sorensen and coworkers [71] reported that cyclical E and antagonizes NF-kB activity in human hepatoma HepG2 2 norethisterone did not improve endothelial function. We cells [76] . 
.4.1. Cell adhesion molecules LDL cholesterol, Lp(a), and HDL cholesterol levels based Oxidized LDL and its membrane components have been on experimental studies showing stimulatory (LDL [91], shown to induce the expression of inflammatory CAMs on
Lp(a) [92] ) or inhibitory (HDL) [93] effects of these the endothelial cell surface [77] . Serum concentrations of lipoproteins on CAM expression. However, no significant vascular CAM-1 (VCAM-1), intercellular CAM-1 (ICAMor consistent correlations were determined. We speculate 1), and L-selectin, also an adhesion molecule, have been the inhibitory mechanisms of estrogen on expression of reported to be higher in patients with coronary artery CAMs are multifactorial: increase in NO and HDL cholesdisease than in healthy controls [78, 79] . Moreover, men in terol, decrease in LDL cholesterol and Lp(a), protection of the Physician's Health Study with the highest quartile of LDL from oxidation, and direct inhibition of NFkB ICAM-1 levels were found to be at greater cardiovascular activation (Fig. 3) . risk than men in the lowest quartile [80] . Plasma concentrations of ICAM-1 increased with increasing preval-4 .4.2. Monocyte chemoattractant protein-1 ence of usual cardiovascular risk factors in healthy men Some cell culture and animal studies observed that E 2 [81] .
inhibited the increase in monocyte chemoattractant protein The selectin family of adhesion molecules, which in-(MCP)-1 and mRNA expression [94, 95] . We recently cludes L-selectin and E-selectin, binds to carbohydrate observed that CEE with MP or MPA significantly deligands on leukocytes and promotes 'rolling' of these creased MCP-1 levels from baseline values in healthy cells-the first step in adhesion-on activated endothelium postmenopausal women (P,0.005 by ANOVA) (Fig. 4 ) prior to the firm adherence of ICAM-1 and VCAM-1, with [72, 96] , which were consistent with a preliminary study by subsequent incorporation into the vessel wall. The Stork et al. [97] . As to its clinical significance, restenotic pathophysiological relevance of E-selectin in humans has patients had statistically significant (P,0.0001) elevated been suggested by its localization in atherosclerotic levels of MCP-1 compared with nonrestenotic patients plaques [82] , higher levels of E-selectin in patients with after coronary angioplasty [98] . Stable and unstable angina coronary artery disease or carotid artery atherosclerosis patients had statistically significant (P,0.001) elevated relative to controls, and correlation of E-selectin levels levels of MCP-1 compared with controls, particularly with carotid artery wall thickness by ultrasound [83] .
higher levels in unstable angina than in stable angina [99] . Conflicting findings have been reported from cell culture Moreover, increased MCP-1 was significantly correlated studies regarding the effect of estrogen on CAM expreswith increased monocyte activity, as reflected by enhanced sion. E pretreatment for 48 h was found to inhibit O generation [98, 99] . response, enter the circulation and have biological effects Studies of the effects of HRT on CAMs in postat a distance from the site of inflammation, including the menopausal women have been promising. Koh et al. [86] activation of genes within hepatocytes that encode specific first reported the effects of either transdermal E or proteins (Fig. 5) . These acute phase reactants include 2 transdermal E and oral MPA on inflammatory CAMs in fibrinogen, C-reactive protein (CRP), and serum amyloid 2 postmenopausal women, which lowered CAM levels from A [100] . CRP may induce the synthesis of cytokines, the baseline. In a randomized, double-blind, crossover CAMs, and tissue factor in monocytes and endothelial study, 6 or 8 weeks of treatment with CEE alone or cells [100] [101] [102] . Tissue factor activates the extrinsic combined with micronized progesterone (MP) or MPA coagulation cascade, providing a link between inflammasignificantly diminished E-selectin, ICAM-1, and VCAM-1 tion and thrombosis. In addition, CRP may contribute to expression compared with baseline (Fig. 4) [54, 55, 72] . The atherogenesis by facilitating uptake of LDL by macroPostmenopausal Estrogen / Progestin Interventions (PEPI) phages, thus accelerating foam cell formation [103] . trial confirmed the reduction of E-selectin by HRT [87] .
Ridker et al. [104] reported the predictive value of CRP Serum concentrations of E-selectin, ICAM-1, and VCAMin determining the risk of future cardiovascular events in 1 have been reported to be higher in postmenopausal 122 apparently healthy participants in the Women's Health women with coronary artery disease not taking HRT than Study who subsequently suffered a first cardiovascular postmenopausal women with coronary artery disease takevent during a 3-year follow-up period. They found that ing HRT at the time of cardiac catheterization [88] . Several women who developed cardiovascular events had higher recent papers reported the same observations [89, 90] .
baseline CRP levels than control subjects. In another study In order to identify a mechanism for the CEE treatment
[105], median CRP levels were twice as high among effects on CAMs, Koh et al. [54, 55] assessed correlations women taking HRT than among women not taking HRT between changes in levels of E-selectin and changes in (0.27 vs. 0.14 mg / dl; P50.001) in 493 healthy post- menopausal women. The PEPI Study showed that HRT in response to both transient myocardial ischemia and regimens resulted in a large sustained increase in levels of reperfusion [113] , and persistent overexpression of TNF-a CRP with a decrease in E-selectin levels [87] . Others have after ischemia might lead to adverse coronary outcomes reported the same observations with oral HRT [114] . TNF-a levels increased acutely with coronary [73, 89, 90, [106] [107] [108] . In contrast, transdermal administraischemia [115] , and plasma levels of TNF-a were persistion of ERT significantly lowered CRP levels [109, 110] or tently elevated among post-myocardial infarction patients did not change CRP levels [89] in postmenopausal women.
at increased risk for recurrent coronary events [116] . TNFa was expressed in donor heart cardiac myocytes and 4 .4.4. Tumor necrosis factor-a predicted right ventricular failure early after human heart TNF-a is a multifunctional circulating cytokine derived transplantation [117] . from endothelial and smooth muscle cells as well as Experimentally, estrogen blocks monocyte / macrophage macrophages associated with coronary atheroma (Fig. 5) .
production of TNF-a by decreasing the activity of Jun Further, TNF-a enhances the rate of monocyte recruitment NH -terminal kinase [118] . We observed that CEE with 2 into developing atherosclerotic lesions [111] . TNF-a is MP or MPA significantly reduced TNF-a levels from the involved in several cardiovascular processes. The associabaseline in hypertensive or overweight postmenopausal tion of accumulation of LDL in rat arteries and activation women and, furthermore, patients with the highest baseline of TNF-a expression suggests a possible mechanism for of TNF-a levels showed the greatest extent of reductions the inflammatory response in the early stages of athero- [119] . Our observation was consistent with the findings of sclerosis [112] . TNF-a is upregulated in the myocardium Walsh et al. [108] . [120] demonstrated that IL-6 mRNA and only with oral estrogen compared with transdermal esprotein were expressed in the atherosclerotic plaques of trogen, as reported by Koh et al. [52] and others [89, 121] . apoE-knockout mice aortas; treatment of male apoEknockout mice with E for 3 weeks resulted in a statistical-4 .5. Clinical implications 2 ly significant 50% reduction (P,0.01) in IL-6 secretion from ex vivo aortic tissue segments, suggesting the anThe determination of endothelial dysfunction has been tiatherosclerotic effects of E . The effects of ERT or HRT found to be a sensitive and specific screening test to 2 on soluble IL-6 levels in postmenopausal women are predict the presence of CVD [122] [123] [124] . Gaeta et al. [123] inconsistent. Some studies observed the increase in reported that the offspring of patients with premature levels [90, 107] , whereas our study and others observed no myocardial infarction had lower flow-mediated dilation significant changes [106, 108] . compared with the control subjects. Vascular inflammation In summary, the effect of HRT on inflammation in plays an important role in the pathogenesis of atheropostmenopausal women varies because orally administered sclerosis and may contribute to increase the risk of HRT increases the levels of CRP and, on the other hand, myocardial infarction and stroke. Plasma levels of indecreases levels of the soluble CAMs, MCP-1, TNF-a that flammatory markers were increased and correlated with the may contribute to the risk of CVD (Table 1) . Although extent of disease in patients with atherosclerosis of the likely a first pass effect of orally administered estrogen on coronary and peripheral arteries [125] . Hingorani et al. the hepatic synthesis of CRP, elevated CRP could have [126] demonstrated that acute systemic inflammation with deleterious effects on vascular inflammation, as discussed Salmonella typhi vaccine impaired endothelium-dependent previously, and may have contributed to the unexpected dilation in humans. Also of interest, Raza et al. [127] increase in myocardial infarction risk within the first year reported that flow-mediated dilation was significantly of treatment in the HERS [11] . The response of CRP only impaired in adults with primary systemic necrotizing to oral route preparation is similar to the response of vasculitis. Furthermore, suppression of inflammation re- stored and normalized impaired endothelial function in integrity of both the endothelium and ER populations in these patients.
endothelial cells and vascular smooth muscle cells, and Accordingly, therapies that improve endothelium-depenthese conditions were probably not met by most women in dent dilation and reduce vascular inflammation may reduce the HERS trial because of their advanced age and coronary cardiovascular risk. ERT or HRT improves endotheliumatherosclerosis [129, 130] . Optimization of estrogen's cardependent dilation in postmenopausal women. However, dioprotective properties may depend on maintenance of a the effects of ERT or HRT on inflammation in posthealthy endothelium. This includes a prudent, low-fat diet, menopausal women are divergent: orally administered smoking cessation, more physical activity, and enhanced estrogen increases the levels of CRP, but decreases levels efforts by clinicians to diagnose and treat hypertension or of the soluble CAMs, MCP-1, and TNF-a. Reduction of diabetes. soluble cell adhesion molecules, chemokines, and cytoOther randomized, placebo-controlled trials are under kines might protect against atherosclerotic development way and hopefully will answer many of the questions and and progression in women.
concerns raised regarding HRT in postmenopausal women So, where are we left at present with regard to HRT and with coronary artery disease. The Women's Lipid Lower-CVD in postmenopausal women? Perhaps the most iming Heart Atherosclerosis Trial (WELL-HART) and portant current need is greater appreciation of the complexWomen's Atherosclerosis Vitamin / Estrogen Trial (WAVE) ities associated with understanding the cardiovascular are secondary prevention trials and will be completed effects of steroid hormones. Although we await the results soon. Until the results of these trials are available, elderly of large, prospective, randomized trials, such as the women with coronary artery disease should not be started Women's Health Initiative (WHI) and Women's Internaon HRT, but may be left on previously prescribed HRT, as tional Study of Long-Duration Oestrogen After the menoadverse events seemed to occur relatively soon after pause (WISDOM), many observational studies support the initiation of therapy [12] . Instead, lipid-lowering therapy conclusion that the use of HRT has cardiovascular benefit with statins, aspirin, or angiotensin-converting enzyme in healthy postmenopausal women (primary prevention) inhibitors may provide morbidity and survival benefit, as [128] . The fact that HRT did not confer cardioprotective suggested by the clinical trials [131, 132] . If women want effects in the HERS can be assimilated readily according to take HRT, the combination of statin with estrogen may to the 'healthy endothelium' concept. In short, the favorattenuate the potential harmful effects of estrogen therapy able vascular effects of estrogen on atherosclerosis, inflamin postmenopausal women, and maximize any benefit to mation, vasomotion, and hemostasis are dependent on the cardiovascular risk [54, 106, 133] . Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model.
